DAX25.278 +1,1%Est506.103 +1,4%MSCI World4.343 -0,1%Top 10 Crypto8,6100 ±-0,0%Nas22.754 +0,8%Bitcoin56.223 -1,3%Euro1,1786 -0,6%Öl70,28 +4,3%Gold4.977 +2,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Bayer BAY001 Rheinmetall 703000 Siemens Energy ENER6Y SAP 716460 NVIDIA 918422 Deutsche Telekom 555750 Infineon 623100 Amazon 906866 Siemens 723610 Lufthansa 823212 Microsoft 870747 BASF BASF11 RENK RENK73 DroneShield A2DMAA Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Dow letztlich fester -- DAX schließt stärker -- Buffetts letztes Depot als Berkshire-CEO -- eBay, Figma, Palantir, Meta, NVIDIA, Palo Alto, Rüstungsaktien, Infineon, Gerresheimer, Bayer im Fokus
Top News
Trotz Milliarden-Investitionen: Warum die NVIDIA-Aktie vom KI-Ausgabenrausch nicht automatisch profitiert Trotz Milliarden-Investitionen: Warum die NVIDIA-Aktie vom KI-Ausgabenrausch nicht automatisch profitiert
Figma-Aktie springt zweistellig hoch: Umsatz übertrifft die Erwartungen Figma-Aktie springt zweistellig hoch: Umsatz übertrifft die Erwartungen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
KI und Robotik verändern die Wirtschaft. Mit diesem Amundi ETF kannst du in die Treiber dieser Revolution investieren. Hier mehr erfahren.

Eli Lilly Aktie

Kaufen
Verkaufen
Eli Lilly Aktien-Sparplan
866,40 EUR -6,90 EUR -0,79 %
BMN
1.020,55 USD +0,60 USD +0,06 %
nachbörslich
BTT
Eli Lilly jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.829,04 Mrd. EUR

KGV46,82Div. Rendite0,56%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN858560

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS5324571083

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolLLY

Eli Lilly Aktien News

DatumMeistgelesen
PR NewswireLilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks
PR NewswireLilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial
PR NewswireLilly Announces Details of Presentations at ESMO Congress 2023
PR NewswireLoxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PR NewswireLilly Announces Leadership Transitions
PR NewswireLilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
PR NewswireU.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer
PR NewswireUS FDA approves Jardiance® for the treatment of adults with chronic kidney disease
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireLilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference
PR NewswireLilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer
PR NewswireLilly Completes Acquisition of Versanis Bio
PR NewswireLilly Completes Acquisition of Sigilon Therapeutics
PR NewswireLilly Completes Acquisition of DICE Therapeutics
PR NewswireLilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements
PR NewswireLilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Adva...
PR NewswireTirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies
PR NewswireLilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement
PR NewswireLilly Announces Extension of Tender Offer to Acquire DICE
PR NewswireResults from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA
PR NewswireMedicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases
PR NewswireMedicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases
PR NewswireLilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases
PR NewswireLilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC
PR NewswireNew England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PR NewswireLilly to Acquire Sigilon Therapeutics
MyDividendsEli Lilly gibt Dividende für das dritte Quartal bekannt
PR NewswireLilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity...
PR NewswireLilly Declares Third-Quarter 2023 Dividend
PR NewswireLilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes
PR NewswireLilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 we...
PR NewswireUS FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older
PR NewswireLilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions
PR NewswireLilly Teams up with the American Diabetes Association and Adam Duvall to Launch "Tap the Cap"
PR NewswireLilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
PR NewswireFirst-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention
PR NewswireLilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting
PR NewswireLilly to Participate in Goldman Sachs Global Healthcare Conference
PR NewswireLilly ESG Report Highlights Progress Towards Sustainability Goals

Eli Lilly News

Eli Lilly News: auf dieser Seite finden Sie alle Eli Lilly News und Nachrichten zur Eli Lilly Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eli Lilly News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eli Lilly News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.